Video Tag: Metastatic Breast Cancer

A new metastatic breast cancer trial with a “switchable” CAR-T therapy

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options. This is the first study of the sCAR-T platform in solid tumors. CAR-T therapy has been transformative for patients with hematological malignancies who failed numerous prior treatments. However, conventional CAR-T therapies have not yet been as successful at treating patients with solid tumors. This challenge is what Calibr-Skaggs’ switchable CAR-T cell therapy platform was designed to address.